5 Measles Facts Ignored by Mainstream Media

  1. Nobody knows how many people die globally from measles.

Global death statistics and statistics claiming to prove how many lives are saved by vaccinations are produced via computer modelling through the use of assumptions and mathematical algorithms. Two modelling systems are used: Lives Saved Tool (LiST) is used increasingly by donor organizations, and the WHO/IVB model used by the World Health Organization’s Department of Immunization, Vaccines and Biologicals.

Both have their shortfalls:

For example, WHO modelling assumes that all unvaccinated children will have a measles infection by their 20th birthday [1], and a proportion of those cases (ascertained by expert panel) would die from measles.

The LiST tool assumes that the ‘herd’ is protected when vaccination coverage reaches 90%, even though we know that outbreaks still occur in areas with 99% vaccination rate [2].

As an example of how these different modelling systems, with their inbuilt assumptions, can affect the numbers, researchers estimated measles deaths for the year 2000 via the two modelling systems. One model estimated 671,521 deaths, while the other model estimated 224,084 deaths – less than half [1].

2. Measles is notoriously hard to diagnose.

Once upon a time, anybody with a fever and a generalized rash may have been diagnosed with measles. In 1998, only a mere 14% of measles diagnoses turned out to be correct in Australia [3] (Even today, 1 in 10 of all medical diagnoses are incorrect, according to the Society to Improve Diagnosis in Medicine [4]).

Even with widespread use of laboratory screening to confirm or rule out measles, correct diagnoses are not guaranteed, for two reasons:

  • Diagnostic bias promoted by health authorities. For example, the CDC advice to health professionals is “To minimize the problem of false positive laboratory results, it is important to restrict case investigation and laboratory tests to patients most likely to have measles”. Those “most likely” to have measles, of course, are the unvaccinated and those who’ve recently travelled abroad. This, of course, serves to reinforce the current paradigm that vaccination ‘works’ and measles has been eliminated from the US, and the only reason outbreaks still occur is because of travellers and the unvaccinated [5].
  • Laboratory testing is not guaranteed to be correct. The specimen needs to be collected at just the right time, and stored under the right conditions. According to the World Health Organization, dengue fever, chikungunya and zika viruses can also present with fever and rash…and test positive for measles – due to “non-specific reactions or formation of immune complexes that can produce a false positive IgM result in measles or rubella IgM assays [6].”

3. Vitamin A saves lives…but apparently is not as profitable as vaccines.

It has been known for decades that supplementing with Vitamin A substantially reduces mortality rates from infectious diseases in developing countries. In the case of measles, Vitamin A supplementation can halve the mortality rate [7].

In the early 1990’s, control of Vitamin A deficiency in developing nations was declared a major international goal, and lauded as possibly the most cost effective of all health interventions [8-9]. This is because sufficient levels of Vitamin A not only benefit overall health and immunity, but also prevent blindness. Why is it then, that decades later, a country like Rwanda has a 98-99% vaccination rate, but only 3% rate of Vitamin A supplementation [10]?

In developing countries, Vitamin A may be administered intravenously in hospitalized measles cases, but oral Vitamin A supplementation is not promoted for home use (which would potentially avert the need for hospitalisation) [11].

4. How the measles virus was supposedly ‘isolated’

The measles component in today’s vaccine was developed in 1954, by scientist John Enders. In a paper published by The American Journal of Public Health, Enders described how he did it [12]:

First, his team obtained ‘throat washings and blood’ from an 11-yo boy with measles named David Edmonston. When he added it to a specimen of ‘post-natal cells’ (cervical cord? Infant foreskin?), these cells fell ill. He assumed this was caused by the measles virus.

He then added the mixture to a culture of HeLa cells – human cervical cancer cells that are so aggressive, and so prolific, they have managed to contaminate many cell lines all over the world. The fluid that ran out, he poured onto a second culture of cells, and then a third, and so on, until he could see under microscope ‘giant multinuclear cells’. He attributed this to measles virus, not to aggressive cervical cancer cells.

He then passaged the fluid through human kidney cells numerous times, followed by numerous passages through human amnion cells, each passage undoubtedly creating more stress and mutations for the cells. When he injected the resulting fluid into monkeys, some got a ‘mild illness’ that in ‘some aspects’ resembled measles. This was all the proof Enders needed, that he had isolated the viral culprit causing illness in kids.

Enders decided using monkeys was too expensive, so went with chicken embryos to save costs, and today’s vaccine is still prepared on chicken eggs [13].

5. Measles Used to Treat Cancer

In 1973, the British Medical Journal published a case study, describing remission of infantile Hodgkin’s disease after natural measles infection [14]. The 23-month-old child developed measles, before radiotherapy could be started, and the researchers noted, “much to our surprise, the large cervical mass vanished without further therapy”.

In fact, vaccine-strain measles is currently being investigated as a potential treatment for cancer, with early results deemed as “promising”, with open trials still being conducted [15]. Earlier research stated that attenuated live measles virus demonstrated “propensity to preferentially infect, propagate in, and destroy cancerous tissue” [16]. 

It was explained that the reason for using modified viruses was “concerns regarding the potential of wild-type-viruses to cause serious side effects, technical limitations in manufacturing viral lots of high purity for clinical use, as well as the overwhelming excitement and fervent support the, at the time, newly emerging chemotherapy approaches that slowed down research on alternative strategies [17]”.

(Note also that a laboratory-engineered virus strain can be patented, which makes it much more desirable for drug companies).

In 2014, CNN aired the story of a woman with incurable multiple myeloma, who had already endured every type of chemotherapy available for that kind of cancer, two stem cell transplants, yet relapsed time and time again [18].

Scientists from the Mayo Clinic injected the woman with a genetically-engineered measles virus. The woman than experienced a high fever of 105, and vomiting (but declared it was the ‘easiest treatment’ she’d done by far). She went into remission for nine months, and then a small growth had to be removed surgically.

But was it the ‘measles’ virus that affected the cancer, or was it the purgative and cleansing action of the fever and vomiting – self-correcting mechanisms of the human body that are now largely suppressed through modern medicine?

In 1890, a young surgeon at New York City’s Memorial Hospital became dismayed at the frequent failures of surgery to treat cancer. His name was William Coley. He began to dig through the records of the hospital, and was intrigued to find the case of an immigrant dockworker, who was admitted to the hospital with a malignant tumour on his neck. He was later discharged without any treatment…and without any further sign of tumour on his neck [19].

William Coley tracked the man down, and found him in good health. It turned out that while the man was in hospital awaiting surgery, he developed a severe case of erysipelas, a painful red inflammation on the skin, accompanied by high fevers. The sarcoma on his neck vanished.

Coley began to experiment on those with inoperable cancers, by injecting bacterial endotoxins to produce a high fever, with an estimated cure rate of 60% (far surpasses the success rate of today’s treatment for stage 4 cancers). Note that the treatment was only successful if fever and skin eruption could be induced.

His product, Coley’s Toxins, was used all over the United States and Europe, but in the post-war years, when science and medicine were enthralled by the promise of ‘cutting edge’ technology such as radiation and chemotherapy, ‘fever therapy’ fell out of favour, and in 1962, Coley’s Toxins were banned by the Food and Drug Administration.

Ironically, ‘immunotherapy’ to treat cancer is now regarded as the ‘hottest area of cancer research’ [20]. Perhaps, if we looked at why people’s immune system had become so dysregulated to start with…?

Other random findings:

While still on the subject of measles, it would appear the current MMR vaccine was approved without having been tested in clinical trials, but rather, based on studies of the individual components.

The vaccine insert for the current MMR II vaccine references numerous studies, but they are ALL for the individual components of the vaccine, not the MMR vaccine [21].

There is one (small) study mentioned that appears to have been based on the MMR II vaccine but…no references are provided.

Clinical trials are generally conducted in phases of ever-increasing numbers of participants. Phase 1 trials usually involve 20-100 healthy volunteers. Phase II usually involves 100-300 volunteers from the target market. And phase III usually involves 300-3000 volunteers from the target market. So, we’d expect to see more than just one study referenced for a new vaccine.

A visit to Merck’s website leaves us none the wiser. The same small study is promoted, but still, puzzlingly, no references are given for said study [22].

Since being approved, more and more adverse reactions have become apparent [23]:

Additionally, Merck stopped making the single vaccines in 2009, so if one wanted to be vaccinated for ‘measles’, they must have the triple-antigen vaccine [24].


 [1] Chen WJ. Comparison of LiST measles mortality model and WHO/IVB measles model. BMC Public Health. 2011;11 Suppl 3(Suppl 3):S33. Published 2011 Apr 13. doi:10.1186/1471-2458-11-S3-S33.

[2] Boulianne N, De Serres G, Duval B, Joly JR, Meyer F, Déry P, Alary M, Le Hénaff D, Thériault N. Département de santé communautaire, Centre Hospitalier de l’Université Laval. [Major measles epidemic in the region of Quebec despite a 99% vaccine coverage] [Article in French]. Can J Public health. 1991 May-Jun;82(3):189-90].

[3] Francombe H. Measles diagnosis unreliable, Australian Doctor, Feb 18, 2000.].

[4] Society to Improve Diagnosis in Medicine. Reducing Harm From Diagnostic Error, http://www.improvediagnosis.org/. Accessed October, 2017

[5] Centers for Disease Control and prevention, Manual for Surveillance of Vaccine-preventable Diseases: Measles, https://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html. Accessed February, 2019.

[6] WHO, Manual for the Laboratory-based Surveillance of Measles, Rubella, and Congenital Rubella Syndrome, https://www.who.int/immunization/monitoring_surveillance/burden/laboratory/manual_section4.2/en/. Accessed February, 2019.

[7] SOMMER A. Vitamin A prophylaxis, Archives of Disease in Childhood 1997;77:191-194.

[8] World Bank. World development report 1993: investing in health. Washington DC: World Bank/New York: Oxford University Press, 1993.

[9] National strategies for overcoming micronutrient malnutrition. 45th World Health Assembly (agenda item 21), 1992. World Health Organisation, Geneva.

[10] UNICEF, Statistics: Rwanda, https://www.unicef.org/infobycountry/rwanda_statistics.html#114. Accessed September, 2017.

[11] Mayo Clinic, Measles: https://www.mayoclinic.org/diseases-conditions/measles/diagnosis-treatment/drc-20374862. Accessed February, 2019.

[12] Enders J et al, Measles Virus: A Summary of Experiments Concerned with Isolation, Properties and Behavior, Am J Pub Health, 1957, 47(3):275-282.

[13] CDC, Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013 Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMRW, 2013, 62(4), pp 8.

[14] Mota C. Infantile Hodgkins’ disease: remission after measles. BMJ, 1973; 2(5863): 421.

[15] Aref S, Bailey K, Fielding A. Measles to the Rescue: A Review Of Oncolytic Measles Virus. Viruses, 2016; 8(10):294.

[16] Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: An overview. Curr Opin Mol Ther, 2009, 11(1): 43-53.

[17] ibid

[18] CNN, Measles virus used to put woman’s cancer into remission, https://edition.cnn.com/2014/05/15/health/measles-cancer-remission/index.html. Accessed February, 2019.

[19] Engelking C, Germ of an Idea: Coley’s Cancer-Killing Toxins, Discover Magazine, http://discovermagazine.com/2016/april/11-germ-of-an-idea. Accessed February, 2019

[20] Ibid

[21] FDA, MMR II vaccine, https://www.fda.gov/downloads/BiologicsBloodVaccines/UCM123789.pdf. Accessed February 2, 2019.

[22] MerckVaccines.com, Seroconversion Rates, https://www.merckvaccines.com/products/mmr/seroconversion-rates. Accessed February, 2019.

[23] FDA, Measles, Mumps and Rubella Virus Vaccine, Live, https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094050.htm. Acessed February 2, 2019.

[24] CDC, Q&A’s About Monovalent MMR vaccines, https://www.cdc.gov/vaccines/hcp/clinical-resources/mmr-faq-12-17-08.html. Accessed February 2, 2019.

Viagra (& Other Drugs) Found in Vaccine For Infants?

In December, 2018, Italian research group, Corvelva, announced they had received a donation from the Italian National Order of Biologists, and intended to test the contents of every vaccine currently on the market.

Their first results were shocking, but predictably overlooked by mainstream media. They found that Infanrix Hexa (6-in-1 vaccine currently used in Australia, UK, and other countries) didn’t even contain one antigen that was purported to be in the vaccine, but did contain chemical toxins and contaminants, many of which were unrecognisable [1].

Recently, more results were released, this time for Sanofi’s Hexacima/Hexyon – another 6-in-1 vaccine, currently licensed in Europe for infants from 6 weeks of age – and these results are just as disturbing…

Not only did they fail to find antigens for hepatitis B, Hib or poliovirus, they found over 200 chemicals and contaminants, of which 70% could not be identified in any chemical database [2].

Of those that were identified (to be verified via tandem mass spectrometry testing):

ANTU (alpha-Napthylthiurea): Rat poison, widely used in the 1940’s, but no longer licensed for use in the US, UK or European Union. Repeated exposure can injure the thyroid and adrenals, leading to hypothyroidism [3].

Benzofluorine: component of coal tar, cigarette smoke and smog, carcinogenic [4] [A component of some diuretic blood-pressure medications. Side effects may include dizziness, skin rashes (dermatitis), altered blood count, changes in metabolism [5].

Celecoxib: non-steroid anti-inflammatory drug (NSAID), Cox 2 inhibitor (inhibits the action of prostaglandins), similar to Vioxx. Side effects may include: fainting, kidney failure, bleeding, blurred vision, water retention, drowsiness, itchy rash. May increase risk of heart attacks and stroke [6].

Diethylatrazine: Pesticide, second most widely used pesticide in the US (after glyphosate), but banned in Europe due to persistent groundwater contamination. It is suspected to be an endocrine disrupter and reproductive toxin. Studies found that the chemical caused male frogs to develop female characteristics, possibly because testosterone levels decreased by 10 times, when exposed to atrazine at just 25 ppb (parts per billion) [7].

Gliotoxin: Major (and most potent) mycotoxin produced by aspergillus moulds [8].

Hydrocortisone Cypionate: Synthetic cortisone, possible side effects include: internal bleeding, increased white blood cell production, sleeplessness, Cushing’s Syndrome, osteoporosis, Lupus-like symptoms, seizures, heart failure [9].

Lovastatic Acid: The active, acid form of Lovastatin – a cholesterol-lowering ‘statin’ drug, whose side-effects may include jaundice, loss of appetite, unusual bleeding or bruising, hives, flu-like symptoms, abdominal pain [10].

Mibefradil: calcium-channel blocker, drug formerly used to treat hypertension, but withdrawn from the market in 1998 due to potential harmful interactions with other drugs: “Mibefradil reduces the activity of certain liver enzymes that are important in helping the body to eliminate many other drugs. Inhibiting these enzymes can cause some of these other drugs to accumulate in the body to dangerous levels [11].”

Pymetrozine: Insecticide, listed as ‘likely’ human carcinogen by EPA, due to tumors in animal studies [12].  

Sulfluramid: Insecticide (which contains fluoride), not approved for use in EU. Was due to be phased out in US by 2016. Used in a variety of termite, ant and cockroach baits. Animal studies suggest that sulfluramid may adversely affect the reproductive system, especially in males, and/or cause infertility in males [13].

Tamsulosin: Used by men to treat enlarged prostate. Class of drug known as alpha blocker – these are also used to lower blood pressure as they relax muscles (helping men with enlarged prostate to urinate more easily). Side effects may include low blood pressure and dizziness, pounding heartbeat, and possibly increased risk of heart failure [14].

Valnemulin: Veterinary antibiotic (antimicrobial) – when handling the product, veterinary assistants are advised to wear gloves, and avoid contact with skin or mucus membranes [15]

Viagra (Sildenafil): Although famously used to treat erectile dysfunction, Viagra was originally developed for high blood pressure and angina. Side effects may include: decreased blood flow to the optic nerve, resulting in sudden vision loss, heart attack, sudden hearing loss [16].

[1] [Corvelva, Vaccingate: Initial results on Infanrix hexa chemical composition, Available at: https://www.corvelva.it/speciali-corvelva/analisi/vaccingate-initial-results-on-infanrix-hexa-chemical-composition.html. Accessed 24th January, 2019.

[2] Corvelva, Study on the chemical composition of Hexyon, Available at: https://drive.google.com/file/d/12e3O0cT1hSMGULzvFg3DcoM_XyGZMRur/view. Accessed 24th January, 2019.

[3] Toxicology Data Network, Alpha-Napthylthiurea, https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1512. Accessed 25th January, 2019.

[4] Koganti A, Singh R, Rozett K, Modi N, Goldstein LS, Roy TA, Zhang FJ, Harvey RG, Weyand EH (2000). “7H-benzo[c]fluorene: a major DNA adduct-forming component of coal tar”. Carcinogenesis. 21 (8): 1601–1609.

[5] EMC, Bendroflumethiazide tablets, https://www.medicines.org.uk/emc/product/5726/pil. Accessed 24th January, 2019.

[6] RxList, Cox 2 Inhibitor Medications, https://www.rxlist.com/cox-2_inhibitors/drugs-condition.htm. Accessed 24th January, 2019.

[7] Hayes TB, Collins A, Lee M, Mendoza M, Noriega N, Stuart AA, Vonk A, Hermaphroditic, demasculinized frogs after exposure to the herbicide atrazine at low ecologically relevant doses, Proc Nat Acad Sci, 2002, 99(8): 5476-5480

[8] Kwon-Chung KJ, Sugui JA. What do we know about the role of gliotoxin in the pathobiology of Aspergillus fumigatus?. Med Mycol. 2008;47 Suppl 1(Suppl 1):S97-103.

[9] WebMD, Hydrocortisone Cypionate Suspension Side Effects by Likelihood and Severity, https://www.webmd.com/drugs/2/drug-8792/hydrocortisone-cypionate-oral/details/list-sideeffects. Accessed 25th January, 2019.

[10] Medline Plus, Lovastatin, https://medlineplus.gov/druginfo/meds/a688006.html. Accessed 25th January, 2019.

[11] Meinertz T, Mibefradil — a drug which may enhance the propensity for the development of abnormal QT prolongation, European Heart Journal Supplements, 2001, 3 (Supplement K), K89–K92.

[12] [US Environmental Protection Agency, Pymetrozine, https://www3.epa.gov/pesticides/chem_search/reg_actions/registration/fs_PC-101103_01-Aug-00.pdf. Accessed 25th January, 2019.

[13] US EPA memorandum, “Sulfluramid – Amount of A.I. in Raid Max Roach Bait.” To Mike Mendelsohn, PM Team Reviewer, Registration Division (7505C). From Linda L. Talor, Ph.D., Toxicology Branch II, Health Effects Division (7509C) and Marcia van Gemert, Ph.D., Chief, Toxicology Branch II/HED (7509C), August 10, 1994.

[14] Mayo Clinic, Alpha Blockers, https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/alpha-blockers/art-20044214. Accessed 25th January, 2019.

[15] European Medicines Agency, Annex 1, Summary of Product Characteristics, https://www.ema.europa.eu/documents/product-information/econor-epar-product-information_en.pdf. Accessed 25th January, 2019.

[16] Medical News Today, Uses and Risks of Viagra, Available at: https://www.medicalnewstoday.com/articles/232912.php. Accessed 24th January, 2019. �{�

200+ Future Vaccines: Here’s A Glimpse of What to Expect

In 2013, the Pharmaceutical Research and Manufacturers of America (PhRMA) proudly announced that American biopharmaceutical companies had 271 new vaccines in development [1].

“The 271 vaccines in development span a wide array of diseases, and employ exciting new scientific strategies and technologies. These potential vaccines – all in human clinical trials or under review by the Food and Drug Administration (FDA) – include 137 for infectious diseases, 99 for cancer, 15 for allergies and 10 for neurological disorders”

Here’s a brief glimpse at what we can expect:

  1. A genetically-engineered nasal vaccine for obesity [2].
  2. A vaccine for malaria, using genetically-engineered parasites [3].
  3. A vaccine made from mouse cancer cells, for use in patients with colorectal cancer [4].
  4. A chimeric virus (two viruses genetically engineered/combined into one virus) vaccine for Japanese encephalitis [5].
  5. A genetically-engineered vaccine for Pseudomonas aeruginosa – apparently it is a major cause of hospital-acquired infections [6]. Note that they tested it on ventilated patients in an intensive care unit – as if they didn’t already have enough to deal with! In addition, vaccination made no difference whatsoever to rates of infection…but that didn’t stop them recommending further testing.
  6. A vaccine for Vigoo enterovirus 71…never heard of it, nevertheless, I’m sure they’ll be able to create a market for it [7].
  7. Plant-based oral vaccines for Type-1 diabetes [8].
  8. A vaccine made from genetically-engineered Listeria, for early-stage pancreatic cancer [9].
  9. Genetically-engineered papaya with an inbuilt vaccine for Taenia solium or T. crassiceps – a type of tapeworm found in pigs and humans [10].
  10. A vaccine for stress [11].


[1] Pharmaceutical Research and Manufacturers of America (PhRMA), Medicines in development: Vaccines, http://phrma.org/press-release/medicines-in-development-vaccines. Accessed February, 2017.

[2] Azegami T, Yuki Y, Sawada S, et al. Nano-gel based nasal ghrelin vaccine prevents obesity, Mucosal Immunol, 2017, epub ahead of print.

[3] Kublin JG, Mikolajczak SA, Sack BK, et al. Complete attenuation of genetically engineered plasmodium falciparum sporozoites in human subjects, Sci Transl Med, 2017, 9(371).

[4] Seledtsova GV, Shishkov GV, Kaschenko EA, Seledtsov VI. Xenogeneic cell-based vaccine therapy for colorectal cancer: safety, association of clinical effects with vaccine-induced immune responses, Biomed Pharmac, 2016, 83: 1247-1252.

[5] Kosalaraksa P, Watanaveeradej V, Pancharoen C, et al. Long-term immunogenicity of a single dose of japanese encephalitis chimeric virus vaccine in toddlers and booster response 5 years after primary immunization, Pediatry Infect Dis J, 2016, epub ahead of print.

[6] Rello J, Krenn CG, Locker G, et al. A randomized, placebo-controlled phase II study of a pseudomonas vaccine in ventilated ICU patients, Crit Care, 2017, 21(1): 22.

[7] Wei M, Meng F, Wang S, et al. 2-year efficacy, immunogenicity, and safety of Vigoo enterovirus 71 vaccine in healthy chinese children: a randomized, open-label study, J Infect Dis, 2017, 215(1): 56-63.

[8] Posgai AL, Wasserfall CH, Kwon KC, et al. Plant-based vaccines for oral delivery of type-1 diabetes-related auto-antigens: evaluating oral tolerance mechanisms and disease prevention in NOD mice, Sci Rep, 2017, 7: 42372.

[9] Keenan BP, Saenger Y, Kafrouni MI, et al. A listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice, Gastroenterology, 2014, 146(7): 1784-1794.

[10] Fragoso C, Hernandez M, Cervantes-Torres J, et al. Transgenic papaya: a useful platform for oral vaccines, Planta, 2017, epub ahead of print.

[11] Elliot D. Preventing Mental Illness with a Stress Vaccine, The Atlantic, Nov 26, 2016.

7 Reasons Why Antibodies Can’t Possibly Provide Immunity

There is a massive vaccine industry that rakes in billions in profits, based on the belief that if you have antibodies, you are ‘protected’. Here’s 7 reasons why that belief needs a re-think…


There are numerous cases in the scientific literature, of people succumbing to illness, even though they had high antibody counts [1-3]. In fact, some of those had antibody titres 100x higher than what is considered sufficient to provide ‘immunity’. On the other hand, there are people with little to no antibody counts (and supposedly susceptible) passing through disease outbreaks completely untouched [4].

Actually, the discovery that antibodies are not responsible for immunity was made more than 80 years ago, by immunologist Dr. Merrill Chase, and his discovery was largely ignored by mainstream medicine, despite a long and illustrious career, and publishing more than 150 research papers [5].


According to vaccine logic, the more antibodies you have, the better, but in a NORMALLY functioning immune system, antibody production is tightly restricted (for good reason – more on that later). It’s now common knowledge that Vitamin D is necessary for a healthy immune system…but did you know Vitamin D LIMITS antibody production [6]? It begs the question why, if antibodies really are as vital as we have been led to believe…


The presence of prior antibodies has been found to ENHANCE some diseases. It’s called ‘antibody-dependant enhancement’ and, so far, it has been demonstrated to enhance dengue fever, zika virus, HIV, Ebola, and others [7-12].


Antibodies are created in the body as a last resort. It only occurs AFTER the cells have become infected. Remember the selling point of vaccines – about having a ‘primed’ immune system, so that antibodies could respond faster? Well, technically that’s true, but they neglected to mention that, even in a ‘primed’ immune system, antibodies are STILL not called into action, until after infection occurs [13]. Therefore, it’s a biological impossibility for antibodies to prevent infection, even in a ‘primed’ immune system.


By now, you may be wondering why the human body is designed to limit, restrict or delay antibody production. There’s a good reason for this – because antibodies are highly inflammatory and uncomfortable. Those unpleasant symptoms that you experience when ‘sick’ are not symptoms of disease, they are the result of antibodies. Antibodies place a large burden on the body’s excretory systems and, if not excreted in a timely manner, they conglomerate and form ‘antibody complexes’, which are rather large and tend to get stuck in the soft tissues and joints, causing inflammation and tissue damage [14]. If you get ‘arthritis’ after a vaccine or illness, now you know why! Antibodies!


True immunity requires a robust innate immune system (also known as Th1 immunity). This is the very first line of defence. As already mentioned, vaccines target antibody production, which is part of the humoral immune system (also known as Th2 immunity) – and the last function called into play by the immune system.

We can look upon these two arms of the immune system (innate and humoral) as being antagonistic – when one is dominant, the other is suppressed. So, a dominant antibody response (caused/exacerbated by repeat vaccinations), means that the innate immune system (first line of defence) is suppressed, leaving you more vulnerable to infection [15].

It should be noted here, that the disease known as ‘AIDS’ is characterised by this very same thing – high antibody counts, and poor function of the innate immune system [16]

Also of note – studies have shown that cancer and autism patients have this particular immune imbalance – high antibody counts and suppressed innate immunity [17-20].


Antibodies are extracellular, meaning that they are active outside the cells, but cannot actually enter cells…although scientists are trying to genetically engineer antibodies that will do just that [21].

Now, this is quite a conundrum, because antibodies are not called into action until after a pathogen has entered the cells, and antibodies can only bind to antigens on the surface of the cell (NOT inside the cell).

Now you have to rely on T-cells to orchestrate the killing of infected cells, in order to stop the spread of infection – this is the realm of the innate immune system (the one that is suppressed by repeated vaccinations, remember?). Such is the natural sequence of events when a th1-type response is generated, such as seen in natural infection [22].

The natural Th-1 type response is to eliminate infection via externalising it – this is the classic disease symptoms we know so well, such as rash, fever, cough, mucus, swelling etc [23]. Th2 dominance inhibits this natural response, which inevitably must lead to either:

  • altered disease manifestation, so for example, the vaccinated person who has whooping cough, may have a cough, but without the tell-tale ‘whoop’ sound [24].
  • chronic underlying infection, inflammation or auto-immune disease [25-26].

Let’s just re-emphasize that last point, because it’s really important, and once understood, you’ll never again look at vaccines the same way again…

First: Vaccines are designed to stimulate antibody production (Th2 immune system).

Second: Antibodies cannot stop infection, nor can they enter cells that are infected.

Third: Due to immune imbalance caused by vaccination, infected cells harbour infection chronically, causing inflammation and auto-immune conditions.

Fourth: person shows only mild or no signs of acute illness, but becomes progressively burdened down by chronic health issues.

So, what actually happens is that the vaccine has not prevented infection, it has simply prevented the body from expelling the infection.

It goes without saying, that such a state of affairs does wonders for the vaccine ‘efficacy’ statistics, since the vaccinated are less likely to show overt signs of acute disease, and therefore, less likely to be diagnosed, or even tested – meanwhile, chronic ‘non-communicable’ diseases continue to spiral out of control…

Now you know why.


[1] Crone NE, Reder AT. Severe tetanus in immunized patients with high anti-tetanus titers, Neurology, 1992, 42(4): 761-764.

[2] Maselle SY, Matre R, Mbise R, Hofstad T. Neonatal tetanus despite protective serum antitoxin concentration, FEMS Microbiol Immunol, 1991, 3(3): 171-175.

[3] Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis, 2006, 194(12):1661-1761.

[4] Brodie M, Park W. Active Immunization Against Poliomyelitis, Am J Pub Health, 1936, 26:119–125.

[5] O’Connor A, Merrill W Chase, 98, Scientist Who Advanced Immunology, New York Times, Jan 22, 2004. https://www.nytimes.com/2004/01/22/nyregion/merrill-w-chase-98-scientist-who-advanced-immunology.html. Accessed October, 2018.

[6] Røsjø, E., Lossius, A., Abdelmagid, N., Lindstrøm, J. C., Kampman, M. T., Jørgensen, L., … Holmøy, T. (2017). Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 23(3), 395–402.

[7] Halstead SB, O’Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes, Nature, 1977, 265(5596):739-741.

[8] ] Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans, Science, 2010, 328(5979):745-748.

[9] Dejnirattisai W, Supasa P, Wongwiwat W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent  enhancement of infection with zika virus, Nat Immunol, 2016, 17(9):1102-1108.

[10] Homsy J, Meyer M, Tateno M, et al. The fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells, Science, 1989, 244(4910):1357+.

[11] Furuyama W, Marzi A, Carmody AB, et al. Fcy-receptor Ila-mediated Src signaling pathway is essential for the antibody-dependent enhancement of ebola virus infection, PLoS Pathogen, 2016, 12(12):e1006139.

[12] Biryukov S, Angov E, Landmesser ME, et al. Complement and antibody-mediated enhancement of red blood cell invasion and growth of malaria parasites, EBioMedicine, 2016, 9:207-216.

[13] Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001

[14] Cochrane CG, Dixon FJ. Cell and tissue damage through antigen-antibody complexes. Calif Med. 1969;111(2):99-112.

[15] Brad Spellberg, John E. Edwards; Type 1/Type 2 Immunity in Infectious Diseases, Clinical Infectious Diseases, Volume 32, Issue 1, 1 January 2001, Pages 76–102.

[16] Kaur R, Dhakad MS, Goyal R, Bhalla P, Dewan R (2016) Study of TH1/TH2 Cytokine Profiles in HIV/AIDS Patients in a Tertiary Care Hospital in India. J Med Microb Diagn 5:214

[17] Sato M, Goto S, Kaneko R, et al. Impaired production of Th1 cytokines and increased frequency of Th2 subsets in pBMC from advanced cancer patients. Anticancer Res, 1998, 18:3951-3955.

[18] Huang M, Wang J, Lee p, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res, 1995, 55:3847-3853.

[19] Filella X, Alcover J, Zarco MA, et al. Analysis of type T1 and T2 cytokines in patients with prostate cancer, prostate, 2000, 44:271-274.

[20] Gupta, S., Aggarwal, S., Rashanravan, B., Lee, T., TH1 and TH2-like cytokines in CD4+ and CD8+ T cells in autism, J of Neuroimmunol, 1998; 85:106-109.

[21] Coghlan A. Super-antibodies break the cell barrier, New Scientist, https://www.newscientist.com/article/dn4881-super-antibodies-break-the-cell-barrier/. Accessed December 2018.

[22] Kim EJ, Cho D, Kim TS. Efficient induction of T helper type 1-mediated immune responses in antigen-primed mice by anti-CD3 single-chain Fv/interleukin-18 fusion DNA, Immunology, 2004, 111(1): 27–34.

[23] Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes, Nature, 1996, 383(6603):787-93.

[24] Nelson KE, Williams C. Infectious Disease Epidemiology: Theory and practice 2007), Jones and Bartlett Learning, pp 131.

[25] Hayflick, L. Slow Viruses, Executive Health Report, Feb. 1981, pp 4.

[26] Talai, N., “Autoimmunity,” in Fudenberg, Basic Clinical Immunology, 3rd Ed., Lange, 1980, p. 222.